Temozolomide response predictor and methods
A technology of temozolomide and reaction, which is applied in the field of drug reaction of temozolomide, and can solve problems such as analysis selection that does not propose response prediction
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
example
[0058] Archived FFPE tissue sections were obtained from 41 patients with metastatic colorectal cancer from the FELDSPAR cohort who had received TMZ in one of 3 phase II clinical trials. As shown in Table 1, tumor samples from 41 TMZ-treated patients were available for analysis. The patients had a median age of 69 years and had received a median of 3 chemotherapy regimens prior to TMZ. Most patients had an ECOG status of 0 or 1 (85%); and at least 2 metastatic sites (56%), with the liver being the most common site. As expected in mCRC, all patients eventually progressed to TMZ. ORR was as follows: 26 patients (63%) had progressive disease; 9 (22%) had partial response; 6 (15%) had stable disease. Such as figure 1 As shown, among these 41 samples, 39 successfully passed the quality control criteria for RNAseq sequencing, and 35 successfully passed the quality control criteria for methyl BEAMing (digital MB). The following is a brief analysis of this sample selection.
[005...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


